Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal effects of pausing Weight-Loss drug

NCT ID NCT07387796

Knowledge-focused Sponsor: The University of Texas at Dallas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This study will follow 40 adults aged 18-70 who currently take tirzepatide, a medication for blood sugar and appetite control. Researchers will temporarily stop the drug for 3-4 weeks and then restart it for 6-8 weeks, using brain scans, questionnaires, and stool samples to track changes in brain activity, hunger, mood, and behavior. The goal is to understand how the medication affects the brain and daily life, without offering any direct treatment benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, this study could help doctors understand how tirzepatide affects the brain and behavior, potentially improving treatment plans for weight management and substance use disorders.
What could go wrong
This is a small, early-stage study with only 40 participants and no comparison group, so results may not apply to everyone. The temporary medication pause may cause discomfort or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-70 years. * Currently on tirzepatide. * Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic. * Cognitively capable of understanding and signing informed consent. * Be proficient in English. Exclusion Criteria: * History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization). * Diagnosis of Type 2 Diabetes. * Current diagnosis of an eating disorder. * Use of medications affecting weight other than tirzepatide. * Pregnancy or breastfeeding. * MR contraindications: * Heart pacemaker, heart valve replacement, or aortic clips * Metal fragments in the eyes, skin, or elsewhere in the body * Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass * Venous umbrella * Pieces of metal in the body resulting from work as a sheet-metal worker or welder * Clips placed in an internal organ * Prosthetic devices, such as middle ear, eye, joint, or penile implants * Joint replacement * Hearing aid that cannot be removed * Neurostimulator * Insulin pump * Shunts or stents * Metal mesh or coil implants * Metal plate, pin, screws, or wires, or any other metal implants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug discontinuation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

substance withdrawal syndrome substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug discontinuation Eating behavior changes Substance use disorders Tirzepatide

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for BrainHealth

    RECRUITING

    Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.